Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $150,659 | 4 | 99.6% |
| Consulting Fee | $600.00 | 1 | 0.4% |
| Food and Beverage | $35.32 | 1 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| COVIDIEN LP | $150,523 | 3 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $736.50 | 2 | $0 (2024) |
| Biogen, Inc. | $35.32 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $136.50 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($136.50) |
| 2022 | $600.00 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($600.00) |
| 2019 | $35.32 | 1 | Biogen, Inc. ($35.32) |
| 2018 | $67,705 | 1 | COVIDIEN LP ($67,705) |
| 2017 | $82,818 | 2 | Covidien LP ($82,818) |
All Payment Transactions
6 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $136.50 | Research |
| Study: POST-OP RECOVERY - OREXIN | ||||||
| 11/25/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 10/26/2019 | Biogen, Inc. | SPINRAZA (Biological) | Food and Beverage | Cash or cash equivalent | $35.32 | General |
| Category: NEUROLOGY | ||||||
| 04/06/2018 | COVIDIEN LP | CAPNOLINE (Device) | — | Cash or cash equivalent | $67,705.30 | Research |
| Study: CAPNOGRAPHY AT THE BEDSIDE • Category: PATIENT MONITORING | ||||||
| 10/20/2017 | Covidien LP | CapnoLine (Device) | — | Cash or cash equivalent | $78,317.60 | Research |
| Study: Capnography at the bedside: Leading Education Efforts (CapAble Trial) • Category: Patient Monitoring | ||||||
| 10/20/2017 | Covidien LP | CapnoLine (Device) | — | Cash or cash equivalent | $4,500.00 | Research |
| Study: Capnography at the bedside: Leading Education Efforts (CapAble Trial) • Category: Patient Monitoring | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Capnography at the bedside: Leading Education Efforts (CapAble Trial) | Covidien LP | $82,818 | 2 |
| CAPNOGRAPHY AT THE BEDSIDE | COVIDIEN LP | $67,705 | 1 |
| POST-OP RECOVERY - OREXIN | Takeda Pharmaceuticals U.S.A., Inc. | $136.50 | 1 |
About Dr. Melissa Langhan, MD
Dr. Melissa Langhan, MD is a Pediatric Emergency Medicine healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1083819031.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Melissa Langhan, MD has received a total of $151,295 in payments from pharmaceutical and medical device companies, with $136.50 received in 2024. These payments were reported across 6 transactions from 3 companies. The most common payment nature is "" ($150,659).
Practice Information
- Specialty Pediatric Emergency Medicine
- Location New Haven, CT
- Active Since 06/19/2007
- Last Updated 07/08/2007
- Taxonomy Code 2080P0204X
- Entity Type Individual
- NPI Number 1083819031
Products in Payments
- CapnoLine (Device) $82,818
- CAPNOLINE (Device) $67,705
- SPINRAZA (Biological) $35.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Emergency Medicine Doctors in New Haven
Allen Hsiao, Md, MD
Pediatric Emergency Medicine — Payments: $21,915
Dr. Mark Cicero, Md, MD
Pediatric Emergency Medicine — Payments: $1,395
Dr. Antonio Riera, Md, MD
Pediatric Emergency Medicine — Payments: $25.16
Carl Baum, Md, MD
Pediatric Emergency Medicine
Kirsten Bechtel, Md, MD
Pediatric Emergency Medicine
Linda Arnold, Md, MD
Pediatric Emergency Medicine